Shripal Bhavsar, MD
Radiation Oncology · Oklahoma City, OKNPI 1720254923
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,205 of the $2,860 with a category attached, or 77.1%. AstraZeneca accounts for 79.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $2,229 and has fallen 95.1% since, to $109 in 2025.
Across 33 payments — averaging $86.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Intuitive Surgical$74
- Novartis$61
- Tersera Therapeutics LLC$55
- Takeda Pharmaceuticals U.S.A., Inc.$51
- Merck$43
- plus $307 from 14 others
What the payments were for
- Consulting fees$2,20577%
- Travel & lodging$351%
- Food & beverage$58020%
- Education$401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $2,270 |
| Intuitive Surgical | 1 | $74 |
| Novartis | 3 | $61 |
| Tersera Therapeutics LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Merck | 2 | $43 |
| Incyte Corporation | 2 | $40 |
| Brainlab, Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Myovant Sciences Inc. | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Array Biopharma Inc | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Bayer | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Seagen Inc. | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $16 |
| Sanofi | 1 | $13 |
| Advanced Accelerator Applications | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,205
How this compares
$2,860 in reported general payments places this provider in the 75th percentile of 43 radiation oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 11 | $353 |
| Gabapentin | 12 | $295 |
| Dexamethasone | 12 | $148 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Oklahoma City
- Jerry JaboinOklahoma City$14K
- Christina HensonOklahoma City$9K
- Kiran PrabhuOklahoma City$7K
- Tyler GunterOklahoma City$3K
- Mark McLaughlinOklahoma City$3K
- Leslie YonemotoOklahoma City$3K
- Gary LarsonOklahoma City$2K
- Andrea JohnstonOklahoma City$2K
- Michael ConferOklahoma City$2K
- Ozer AlganOklahoma City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.